Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Gallina, L. Dolcetti, P. Serafini, C. Santo, Ilaria Marigo, M. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, S. Bicciato, V. Bronte (2006)
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.The Journal of clinical investigation, 116 10
W. Matsui, Qiuju Wang, J. Barber, Sarah Brennan, B. Smith, I. Borrello, I. Mcniece, Lan Lin, R. Ambinder, C. Peacock, D. Watkins, C. Huff, Richard Jones (2008)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.Cancer research, 68 1
M. Dhodapkar, E. Abe, A. Theus, Marie Lacy, J. Langford, B. Barlogie, R. Sanderson (1998)
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.Blood, 91 8
M. Sawamura, H. Murakami, J. Tsuchiya (1996)
Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation.Leukemia & lymphoma, 21 1-2
M. Lilienfeld-Toal, S. Frank, C. Leyendecker, S. Feyler, Sarah Jarmin, Ruth Morgan, A. Glasmacher, A. Märten, I. Schmidt-Wolf, P. Brossart, G. Cook (2010)
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linkedCancer Immunology, Immunotherapy, 59
L. Vidal, A. Gafter-Gvili, L. Leibovici, M. Dreyling, M. Ghielmini, S. Schmitz, A. Cohen, O. Shpilberg (2010)
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.Journal of the National Cancer Institute, 101 4
M. Medinger, N. Fischer, A. Tzankov (2010)
Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid MalignanciesJournal of Oncology, 2010
Elliot Jerud, G. Bricard, S. Porcelli (2006)
CD1d-Restricted Natural Killer T Cells: Roles in Tumor Immunosurveillance and ToleranceTransfusion Medicine and Hemotherapy, 33
S Mandruzzato, S Solito, E Falisi, S Francescato, V Chiarion-Sileni, S Mocellin (2009)
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patientsJ Immunol, 182
C. Röllig, C. Schmidt, M. Bornhäuser, G. Ehninger, M. Schmitz, S. Auffermann-Gretzinger (2011)
Induction of Cellular Immune Responses in Patients With Stage-I Multiple Myeloma After Vaccination With Autologous Idiotype-pulsed Dendritic CellsJournal of Immunotherapy, 34
C. Diaz-Montero, M. Salem, M. Nishimura, E. Garrett-Mayer, D. Cole, A. Montero (2008)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 58
A. Gandhi, J. Kang, L. Capone, A. Parton, L. Wu, L. Zhang, D. Mendy, A. López-Girona, T. Tran, L. Sapinoso, W. Fang, S. Xu, G. Hampton, J. Bartlett, P. Schafer (2010)
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.Current cancer drug targets, 10 2
P. Bergsagel, W. Kuehl (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 26
J. Damiano, A. Cress, L. Hazlehurst, A. Shtil, W. Dalton (1999)
Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell LinesBlood, 93
D. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria, J. Prausová, G. Scagliotti, H. Sleeboom, A. Spencer, S. Vadhan-Raj, R. Moos, W. Willenbacher, P. Woll, Jianming Wang, Q. Jiang, S. Jun, R. Dansey, H. Yeh (2011)
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 9
M. Ratta, F. Fagnoni, A. Curti, R. Vescovini, P. Sansoni, B. Oliviero, M. Fogli, E. Ferri, G. Cuna, S. Tura, M. Baccarani, R. Lemoli (2002)
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.Blood, 100 1
M. Bakkus, C. Heirman, I. Riet, B. Camp, K. Thielemans (1992)
Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.Blood, 80 9
A. Letsch, U. Keilholz, G. Assfalg, V. Mailänder, E. Thiel, C. Scheibenbogen (2003)
Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells.Cancer research, 63 17
Gulsum Anderson, M. Gries, N. Kurihara, T. Honjo, Judith Anderson, V. Donnenberg, A. Donnenberg, I. Ghobrial, M. Mapara, D. Stirling, D. Roodman, S. Lentzsch (2005)
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.Blood, 107 8
H. Nitta, K. Mihara, A. Sakai, A. Kimura (2010)
correspondence: Expansion of CD8+/perforin+ effector memory T cells in the bone marrow of patients with thymoma‐associated pure red cell aplasiaBritish Journal of Haematology, 150
P. Maslak, T. Dao, L. Krug, S. Chanel, T. Korontsvit, V. Zakhaleva, Ronghua Zhang, J. Wolchok, Jianda Yuan, J. Pinilla-Ibarz, E. Berman, M. Weiss, J. Jurcic, M. Frattini, D. Scheinberg (2010)
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.Blood, 116 2
C. Peacock, Qiuju Wang, Gregory Gesell, Ian Corcoran-Schwartz, Evan Jones, Jynho Kim, Jynho Kim, W. Devereux, J. Rhodes, C. Huff, P. Beachy, P. Beachy, D. Watkins, W. Matsui (2007)
Hedgehog signaling maintains a tumor stem cell compartment in multiple myelomaProceedings of the National Academy of Sciences, 104
H. Uchiyama, B. Barut, A. Mohrbacher, D. Chauhan, K. Anderson (1993)
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.Blood, 82 12
M. Abe, K. Hiura, Javier Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, D. Inoue, Toshio Matsumoto (2004)
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.Blood, 104 8
D. Chang, Keren Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, Nancy Liu, Rebecca Annable, Jennifer Shay, K. Kirchhoff, N. Nishi, Y. Ando, Kunihiko Hayashi, H. Hassoun, R. Steinman, M. Dhodapkar (2005)
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patientsThe Journal of Experimental Medicine, 201
Yanran Cao, T. Luetkens, S. Kobold, York Hildebrandt, Maja Gordic, Nesrine Lajmi, S. Meyer, K. Bartels, A. Zander, C. Bokemeyer, N. Kröger, D. Atanackovic (2010)
The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.Experimental hematology, 38 10
T. Korn, M. Mitsdoerffer, Andrew Croxford, A. Awasthi, V. Dardalhon, George Galileos, P. Vollmar, Gretta Stritesky, M. Kaplan, A. Waisman, V. Kuchroo, M. Oukka (2008)
IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cellsProceedings of the National Academy of Sciences, 105
A. Zea, P. Rodriguez, M. Atkins, Claudia Hernández, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, J. Mier, A. Ochoa (2005)
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.Cancer research, 65 8
S. Yaccoby, J. Epstein (1999)
The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.Blood, 94 10
V. Tendeloo, A. Velde, A. Driessche, N. Cools, S. Anguille, K. Ladell, E. Gostick, K. Vermeulen, K. Pieters, G. Nijs, B. Stein, E. Smits, W. Schroyens, A. Gadisseur, I. Vrelust, P. Jorens, H. Goossens, I. Vries, D. Price, Y. Oji, Y. Oka, H. Sugiyama, Z. Berneman (2010)
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccinationProceedings of the National Academy of Sciences, 107
L. Zou, B. Barnett, H. Safah, V. Larussa, Melina Evdemon-Hogan, P. Mottram, Shuang Wei, O. David, T. Curiel, W. Zou (2004)
Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 SignalsCancer Research, 64
E. Rossi, D. Rossi, R. Stein, D. Goldenberg, Chien‐Hsing Chang (2010)
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.Cancer research, 70 19
I. Borrello, E. Sotomayor, F. Rattis, S. Cooke, Lingping Gu, H. Levitsky (2000)
Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.Blood, 95 10
L. Pilarski, G. Hipperson, K. Seeberger, E. Pruski, R. Coupland, A. Belch (2000)
Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.Blood, 95 3
M. Weers, Y. Tai, M. Veer, J. Bakker, T. Vink, D. Jacobs, L. Oomen, M. Peipp, T. Valerius, J. Slootstra, T. Mutis, W. Bleeker, K. Anderson, H. Lokhorst, J. Winkel, P. Parren (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 186
Mei‐Chuan Huang, N. Greig, Weiming Luo, D. Tweedie, J. Schwartz, D. Longo, L. Ferrucci, W. Ershler, E. Goetzl (2011)
Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide.Clinical immunology, 138 2
N. Takahashi, G. Mundy, G. Roodman (1986)
Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells.Journal of immunology, 137 11
D. Godfrey, H. Macdonald, M. Kronenberg, M. Smyth, L. Kaer (2004)
NKT cells: what's in a name?Nature Reviews Immunology, 4
Lori Ehrlich, G. Roodman (2005)
The role of immune cells and inflammatory cytokines in Paget's disease and multiple myelomaImmunological Reviews, 208
G. Roodman (2010)
Targeting the bone microenvironment in multiple myelomaJournal of Bone and Mineral Metabolism, 28
M. Medina, A. Quesada, I. Castro, F. Sánchez-Jiménez (1999)
Histamine, polyamines, and cancer.Biochemical pharmacology, 57 12
P. Serafini, Kristen Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, I. Borrello (2006)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionThe Journal of Experimental Medicine, 203
P. Serafini, Stephanie Mgebroff, K. Noonan, I. Borrello (2008)
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.Cancer research, 68 13
K. Dredge, J. Marriott, S. Todryk, George Muller, R. Chen, D. Stirling, A. Dalgleish (2002)
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity1The Journal of Immunology, 168
S. Mandruzzato, S. Solito, Erika Falisi, S. Francescato, V. Chiarion-Sileni, S. Mocellin, A. Zanon, C. Rossi, D. Nitti, V. Bronte, P. Zanovello (2009)
IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients1The Journal of Immunology, 182
M. Brimnes, A. Vangsted, L. Knudsen, P. Gimsing, A. Gang, H. Johnsen, I. Svane (2010)
Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple MyelomaScandinavian Journal of Immunology, 72
Chih-Hsin Tang, Daifeng Lu, Rong-Sen Yang, H. Tsai, M. Kao, W. Fu, Yuh‐Fung Chen (2007)
Leptin-Induced IL-6 Production Is Mediated by Leptin Receptor, Insulin Receptor Substrate-1, Phosphatidylinositol 3-Kinase, Akt, NF-κB, and p300 Pathway in Microglia1The Journal of Immunology, 179
V. Lauta (2003)
A review of the cytokine network in multiple myelomaCancer, 97
F. Chan, R. Siegel, M. Lenardo (2000)
Signaling by the TNF receptor superfamily and T cell homeostasis.Immunity, 13 4
O. Landgren, R. Kyle, Vincent Rajkumar (2011)
From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early InterventionClinical Cancer Research, 17
R. Kyle, T. Therneau, S. Rajkumar, J. Offord, D. Larson, M. Plevak, L. Melton (2002)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.The New England journal of medicine, 346 8
G. Teoh, K. Anderson (1997)
Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma.Hematology/oncology clinics of North America, 11 1
J. Kuball, K. Boer, E. Wagner, M. Wattad, Edite Antunes, R. Weeratna, A. Vicari, C. Lotz, S. Dorp, S. Hol, P. Greenberg, W. Heit, H. Davis, M. Theobald (2010)
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909Cancer Immunology, Immunotherapy, 60
E. Terpos, E. Efstathiou, D. Christoulas, M. Roussou, E. Katodritou, M. Dimopoulos (2009)
RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastasesExpert Opinion on Biological Therapy, 9
R. Knight (2005)
IMiDs: a novel class of immunomodulators.Seminars in oncology, 32 4 Suppl 5
N. Turner, J. Moake, L. McIntire (2002)
Immunocytochemistry reveals RANKL expression of myeloma cells
I. Borrello, R. Vij, R. Vescio, T. Martin, D. Siegel, J. Berenson, F. Janmohamed, M. Bonyhadi, R. Berenson, M. Frohlich (2004)
A phase I/II study of Xcellerated T Cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
H Nitta, K Mihara, A Sakai, A Kimura (2010)
Expansion of CD8+/perforin+ effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasiaBr J Haematol, 150
J. Body, T. Facon, R. Coleman, A. Lipton, F. Geurs, M. Fan, D. Holloway, M. Peterson, P. Bekker (2006)
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 12
A. Mouzaki, Ioannis Panagoulias, Zoe Dervilli, V. Zolota, Panagiota Spadidea, M. Rodi, F. Panitsas, E. Lagadinou, Anne-Lise Lastic, T. Georgakopoulos (2009)
Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells.Cytokine, 48 3
C. Galustian, B. Meyer, M. Labarthe, K. Dredge, Deborah Klaschka, J. Henry, S. Todryk, R. Chen, G. Muller, D. Stirling, P. Schafer, J. Bartlett, A. Dalgleish (2009)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsCancer Immunology, Immunotherapy, 58
J. Taipale, P. Beachy (2001)
The Hedgehog and Wnt signalling pathways in cancerNature, 411
K. Noonan, W. Matsui, P. Serafini, Rebecca Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, Katherine Whartenby, I. Borrello (2005)
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.Cancer research, 65 5
G. Ellis, H. Bone, R. Chlebowski, D. Paul, S. Spadafora, Judy Smith, M. Fan, S. Jun (2008)
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 30
W. Hwang, K. Jung, You-kyoung Jeon, Shik Yun, Tae Kim, I. Choi (2010)
Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors.Vaccine, 29 1
(2011)
Progress and challenges. Clin Immunol, Harnessing natural killer T (NKT) cells in human myeloma
D. Ocadlikova, F. Kryukov, K. Mollová, L. Kovarova, I. Buresdova, Eva Matějková, Miroslav Penka, Tomáš Büchler, Roman Hájek, Jaroslav Michálek (2010)
Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies.Neoplasma, 57 5
Q. Yi, R. Desikan, B. Barlogie, N. Munshi (2002)
Optimizing dendritic cell‐based immunotherapy in multiple myelomaBritish Journal of Haematology, 117
R. Prabhala, Dheeraj Pelluru, M. Fulciniti, Harsha Prabhala, P. Nanjappa, Weihua Song, Christine Pai, S. Amin, Y. Tai, P. Richardson, I. Ghobrial, S. Treon, J. Daley, K. Anderson, J. Kutok, N. Munshi (2010)
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.Blood, 115 26
S. Feyler, M. Lilienfeld-Toal, Sarah Jarmin, L. Marles, A. Rawstron, A. Ashcroft, R. Owen, P. Selby, G. Cook (2009)
CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burdenBritish Journal of Haematology, 144
Xiaoyu Zhang, Haidong Dong, Wei Lin, Stephen Voss, L. Hinkley, Melissa Westergren, Guoliang Tian, D. Berry, D. Lewellen, R. Vile, Lieping Chen, D. Farber, S. Strome (2006)
Human Bone Marrow: A Reservoir for “Enhanced Effector Memory” CD8+ T Cells with Potent Recall Function1The Journal of Immunology, 177
A. Mahindra, T. Hideshima, K. Anderson (2010)
Multiple myeloma: biology of the disease.Blood reviews, 24 Suppl 1
MV Dhodapkar (2011)
Richter J
A. Radbruch, G. Muehlinghaus, E. Luger, A. Inamine, Kenneth Smith, T. Dörner, F. Hiepe (2006)
Competence and competition: the challenge of becoming a long-lived plasma cellNature Reviews Immunology, 6
O. Sezer, U. Heider, C. Jakob, I. Zavrski, J. Eucker, K. Possinger, C. Sers, V. Krenn (2002)
Immunocytochemistry reveals RANKL expression of myeloma cells.Blood, 99 12
S. Vuk-Pavlović, P. Bulur, Yi Lin, R. Qin, C. Szumlanski, Xinghua Zhao, A. Dietz (2010)
Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancerThe Prostate, 70
I. Poschke, D. Mougiakakos, J. Hansson, G. Masucci, R. Kiessling (2010)
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.Cancer research, 70 11
Ross Brown, A. Murray, B. Pope, D. Sze, J. Gibson, P. Ho, D. Hart, D. Joshua (2004)
Either interleukin‐12 or interferon‐γ can correct the dendritic cell defect induced by transforming growth factor β1 in patients with myelomaBritish Journal of Haematology, 125
N. Shah, S. Lonial (2010)
Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.Hematology. American Society of Hematology. Education Program, 2010
A. Rapoport, E. Stadtmauer, N. Aqui, A. Badros, Julio Cotte, Lisa Chrisley, E. Veloso, Zhaohui Zheng, S. Westphal, Rebecca Mair, Nina Chi, Bashi Ratterree, Mary Pochran, Sabrina Natt, Joanne Hinkle, C. Sickles, A. Sohal, K. Ruehle, Christian Lynch, Lei Zhang, D. Porter, S. Luger, Chuanfa Guo, Hong-Bin Fang, W. Blackwelder, K. Hankey, D. Mann, R. Edelman, C. Frasch, B. Levine, A. Cross, C. June (2005)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transferNature Medicine, 11
J. Schmielau, O. Finn (2001)
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.Cancer research, 61 12
C. Brito, M. Naviliat, Adriana Tiscornia, F. Vuillier, Gabriela Gualco, Guillaume Dighiero, Rafael Radi, Alfonso Cayota (1999)
Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death.Journal of immunology, 162 6
N. Robillard, H. Avet-Loiseau, R. Garand, P. Moreau, D. Pineau, M. Rapp, J. Harousseau, R. Bataille (2003)
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.Blood, 102 3
K. Dhodapkar, S. Barbuto, P. Matthews, A. Kukreja, A. Mazumder, D. Vesole, S. Jagannath, M. Dhodapkar (2008)
Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.Blood, 112 7
R. Kyle (1989)
Monoclonal gammopathy of undetermined significance and smoldering multiple myelomaEuropean Journal of Haematology, 43
Ling Zhang, Sid Kerkar, Zhiya Yu, Zhili Zheng, Shicheng Yang, N. Restifo, S. Rosenberg, R. Morgan (2011)
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Molecular therapy : the journal of the American Society of Gene Therapy, 19 4
Ritu Gupta, P. Ganeshan, M. Hakim, R. Verma, Atul Sharma, L. Kumar (2011)
Significantly reduced regulatory T cell population in patients with untreated multiple myeloma.Leukemia research, 35 7
RA Kyle, SV Rajkumar (2007)
Monoclonal gammopathy of undetermined significance and smoldering multiple myelomaHematol Oncol Clin North Am, 21
Miriam Shapiro-Shelef, K. Calame (2005)
Regulation of plasma-cell developmentNature Reviews Immunology, 5
P. Richardson, T. Hideshima, K. Anderson (2002)
Thalidomide: emerging role in cancer medicine.Annual review of medicine, 53
Ambuj Kumar, S. Galeb, B. Djulbegovic (2010)
Treatment of Patients with Multiple Myeloma: An Overview of Systematic ReviewsActa Haematologica, 125
B. Mattioli, E. Straface, M. Quaranta, L. Giordani, M. Viora (2005)
Leptin Promotes Differentiation and Survival of Human Dendritic Cells and Licenses Them for Th1 Priming 1The Journal of Immunology, 174
K. Anderson, Robin Jones, C. Morimoto, P. Leavitt, B. Barut (1989)
Response patterns of purified myeloma cells to hematopoietic growth factors.Blood, 73 7
Q Yi, S Szmania, J Freeman, J Qian, NA Rosen, S Viswamitra (2010)
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patientsBr J Haematol, 150
S. Yaccoby, B. Barlogie, J. Epstein (1998)
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.Blood, 92 8
E. Bettelli, Yijun Carrier, Wenda Gao, T. Korn, T. Strom, M. Oukka, H. Weiner, V. Kuchroo (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 441
J. Du, Zhen-gang Yuan, Chunyang Zhang, W. Fu, Hua Jiang, Baoan Chen, J. Hou (2010)
Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.Leukemia research, 34 11
R. Spíšek, A. Kukreja, Lin-Chi Chen, P. Matthews, A. Mazumder, D. Vesole, S. Jagannath, H. Zebroski, A. Simpson, G. Ritter, B. Durie, J. Crowley, J. Shaughnessy, M. Scanlan, A. Gure, B. Barlogie, M. Dhodapkar (2007)
Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathyThe Journal of Experimental Medicine, 204
N. Abildgaard, H. Glerup, J. Rungby, K. Bendix‐Hansen, M. Kassem, K. Brixen, L. Heickendorff, J. Nielsen, E. Eriksen (2000)
Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myelomaEuropean Journal of Haematology, 64
G. Görgün, E. Calabrese, E. Soydan, T. Hideshima, G. Perrone, Madhavi Bandi, D. Cirstea, L. Santo, Yiguo Hu, Y. Tai, Sabikun Nahar, N. Mimura, C. Fabre, N. Raje, N. Munshi, P. Richardson, K. Anderson (2009)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.Blood, 116 17
W. Matsui, C. Huff, Qiuju Wang, M. Malehorn, J. Barber, Y. Tanhehco, B. Smith, C. Civin, Richard Jones (2004)
Characterization of clonogenic multiple myeloma cells.Blood, 103 6
A. Barber, K. Meehan, C. Sentman (2011)
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cellsGene Therapy, 18
Joseph Sun, S. López-Vergès, Charles Kim, J. Derisi, L. Lanier (2011)
NK Cells and Immune “Memory”The Journal of Immunology, 186
Lori Ehrlich, Ho Chung, I. Ghobrial, S. Choi, F. Morandi, S. Colla, V. Rizzoli, G. Roodman, N. Giuliani (2005)
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.Blood, 106 4
P. Serafini, I. Borrello, V. Bronte (2006)
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.Seminars in cancer biology, 16 1
S. Choi, J. Cruz, Fiona Craig, Hoyeon Chung, R. Devlin, G. Roodman, M. Alsina (2000)
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.Blood, 96 2
Ross Brown, A. Murray, B. Pope, D. Sze, J. Gibson, P. Ho, D. Hart, D. Joshua (2004)
Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.British journal of haematology, 125 6
J. Rosenblatt, B. Vasir, L. Uhl, S. Blotta, Claire Macnamara, P. Somaiya, Zekui Wu, R. Joyce, J. Levine, D. Dombagoda, Y. Yuan, K. Francoeur, D. Fitzgerald, P. Richardson, E. Weller, K. Anderson, D. Kufe, N. Munshi, D. Avigan (2011)
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.Blood, 117 2
K. Noonan, L. Marchionni, Judith Anderson, D. Pardoll, G. Roodman, G. Roodman, I. Borrello (2010)
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.Blood, 116 18
VM Lauta (2003)
A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implicationsCancer, 97
N. Donk, H. Lokhorst, M. Dimopoulos, M. Cavo, G. Morgan, H. Einsele, M. Kropff, S. Schey, H. Avet-Loiseau, H. Ludwig, H. Goldschmidt, P. Sonneveld, H. Johnsen, J. Bladé, J. San-Miguel, A. Palumbo (2011)
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.Cancer treatment reviews, 37 4
J. Harousseau (2010)
Ten years of improvement in the management of multiple myeloma: 2000-2010.Clinical lymphoma, myeloma & leukemia, 10 6
L. Vidal, A. Gafter-Gvili, G. Salles, M. Dreyling, M. Ghielmini, S. Schmitz, R. Pettengell, M. Witzens‐Harig, O. Shpilberg (2009)
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Journal of the National Cancer Institute, 103 23
R Gupta, P Ganeshan, M Hakim, R Verma, A Sharma (2010)
Kumar L
R. Kyle, S. Rajkumar (2007)
Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progressionBritish Journal of Haematology, 139
M. Dhodapkar, J. Krasovsky, Kara Olson (2002)
T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cellsProceedings of the National Academy of Sciences of the United States of America, 99
M. Dhodapkar, J. Krasovsky, Keren Osman, M. Geller (2003)
Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal GammopathyThe Journal of Experimental Medicine, 198
W. Boyle, W. Simonet, D. Lacey (2003)
Osteoclast differentiation and activationNature, 423
J. Agarwal, W. Matsui (2010)
Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis.Anti-cancer agents in medicinal chemistry, 10 2
D. Siegel, R. Vij, R. Vescio, I. Borrello, T. Martin, J. Berenson, C. Ferrand, F. Janmohamed, R. Berenson, M. Frohlich (2004)
A Phase I/II Study of Xcellerated T Cells ™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.Blood, 104
A. Rapoport, N. Aqui, E. Stadtmauer, D. Vogl, Hong-Bin Fang, Ling Cai, Stephen Janofsky, A. Chew, J. Storek, G. Akpek, A. Badros, S. Yanovich, M. Tan, E. Veloso, M. Pasetti, A. Cross, S. Philip, Heather Murphy, R. Bhagat, Zhaohui Zheng, Todd Milliron, Julio Cotte, Andrea Cannon, B. Levine, R. Vonderheide, C. June (2011)
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.Blood, 117 3
W. Gunn, Adam Conley, Lisa Deininger, S. Olson, D. Prockop, C. Gregory (2006)
A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin‐6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple MyelomaSTEM CELLS, 24
William Rifkin (2006)
Denosumab in postmenopausal women with low bone mineral density.The New England journal of medicine, 354 22
N. Giuliani, S. Colla, V. Rizzoli (2004)
New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).Experimental hematology, 32 8
P. Prieto, Katherine Durflinger, J. Wunderlich, S. Rosenberg, M. Dudley (2010)
Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell TherapyJournal of Immunotherapy, 33
K. Noonan, Anna Ferguson, C. Huff, Amy Emerling, Stephanie Mgebroff, R. Wilson, R. Knight, I. Borrello (2008)
The Immunomodulatory Role of Lenalidomide on Prevnar® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune ResponseBlood, 112
N. Tageja (2011)
Lenalidomide - current understanding of mechanistic properties.Anti-cancer agents in medicinal chemistry, 11 3
D. Gabrilovich, S. Nagaraj (2009)
Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 9
M. Lacy (2011)
New Immunomodulatory Drugs in MyelomaCurrent Hematologic Malignancy Reports, 6
T. Schilling, U. Nöth, L. Klein-Hitpass, F. Jakob, N. Schütze (2007)
Plasticity in adipogenesis and osteogenesis of human mesenchymal stem cellsMolecular and Cellular Endocrinology, 271
J. Harousseau (2010)
Multiple myeloma in the elderly: when to treat, when to go to transplant.Oncology, 24 11
B. Mattioli, E. Straface, P. Matarrese, M. Quaranta, L. Giordani, W. Malorni, M. Viora (2008)
Leptin as an immunological adjuvant: enhanced migratory and CD8+ T cell stimulatory capacity of human dendritic cells exposed to leptinThe FASEB Journal, 22
The bone marrow (BM) is the site of disease in myeloma and possesses unique immune characteristics involved in the pathobiology of the disease. Interactions of plasma cells with stromal cells, osteoclasts, osteoblasts, myeloid and lymphoid cells make up the unique bone marrow milieu that mediates myeloma disease progression. Independently or through a complex network of interactions these cells impart immune changes leading to immune evasion and disease progression. The critical role of these factors in disease progression has led to the intense development of therapeutic strategies aimed at either disrupting the immune mechanisms mediating disease progression or augmenting those with anti-tumor benefits. This review discusses the major contributors of immunity in the bone marrow microenvironment, their interactions, and mechanisms whereby immune modulation can be translated into therapies with anti-myeloma efficacy.
Cancer Microenvironment – Springer Journals
Published: Aug 25, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.